Autosomal dominant diffuse Lewy body disease. 1998

K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
Brain Disease Research Center, Brain Research Institute, Niigata University, Japan. koichi@bri.niigata-u.ac.jp

We describe a Japanese family with parkinsonism and later-onset dementia. The proband developed parkinsonism at the age of 61 years, followed by dementia starting when she was 67. Her uncle, who was also her husband, died at the age of 78 years after 7- and 5-year histories of parkinsonism and dementia, respectively. Pathological examination of these two patients showed marked neuronal loss with Lewy bodies (LBs) in the brain stem pigmented nuclei and numerous cortical LBs and ubiquitin-positive hippocampal CA2/3 neurites were observed. The proband also had many amyloid plaques. Their two sons developed similar parkinsonism at the ages of 39 and 28 years and also suffered later-on-set dementia. The apolipoprotein E genotype of the proband, her uncle and one of their sons was epsilon3/4 and that of the other son was epsilon4/4. These findings strongly suggest that this family has autosomal dominant diffuse LB disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E

Related Publications

K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
January 1990, Advances in neurology,
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
December 1995, Rinsho shinkeigaku = Clinical neurology,
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
April 2019, Journal of the neurological sciences,
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
January 1999, Ryoikibetsu shokogun shirizu,
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
December 1997, Rinsho shinkeigaku = Clinical neurology,
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
January 1998, Internal medicine (Tokyo, Japan),
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
August 1989, Lancet (London, England),
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
February 1989, Lancet (London, England),
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
November 2001, Current treatment options in neurology,
K Wakabayashi, and S Hayashi, and A Ishikawa, and T Hayashi, and K Okuizumi, and H Tanaka, and S Tsuji, and H Takahashi
August 2003, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Copied contents to your clipboard!